Other
Change in Deferred Revenue
West Pharmaceutical Services Change in Deferred Revenue increased by 631.3% to $8.50M in Q1 2026 compared to the prior quarter. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
StatementIncome Statement
SectionOther
CategoryGrowth
SignalHigher is better
VolatilityModerate
First reportedQ1 2025
Last reportedQ1 2026Apr 23, 2026
How to read this metric
An increase is generally positive, signaling strong future revenue visibility and customer commitment.
Detailed definition
Measures the net change in payments received from customers for goods or services that have not yet been delivered or ea...
Peer comparison
Highly relevant for subscription or long-cycle businesses; compared against peers with similar revenue models.
Metric ID:
anet_change_in_deferred_revenueHistorical Data
3 periods
| Q1 '25 | Q2 '25 | Q1 '26 | |
|---|---|---|---|
| Value | -$5.40M | -$1.60M | $8.50M |
| QoQ Change | — | +70.4% | +631.3% |
| YoY Change | — | — | +257.4% |
Range-$5.40M – $8.50M
Avg YoY Growth+257.4%
Median YoY Growth+257.4%
Current Streak2+ quarters growth
Change in Deferred Revenue at Other Companies
Frequently Asked Questions
- What is West Pharmaceutical Services's change in deferred revenue?
- West Pharmaceutical Services (WST) reported change in deferred revenue of $8.50M in Q1 2026.
- What does change in deferred revenue mean?
- The change in payments received for work not yet completed.